HUMA Stock Price, Chart, Stats & News

Humacyte, Inc.
Save
177.24M
Market cap
–
Current P/E
35.84x
Forward P/E
HUMA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -134.49% |
Operating margin | -5306.04% |
Pretax margin | -786.51% |
Net margin | -2003.58% |
Effective tax rate | – |
ROA | -35.09% |
ROE | -424.76% |
D/E | 20.86x |
Interest coverage ratio | -21.64x |
HUMA valuation
P/E | – |
P/S | 51.97x |
P/B | 34.37x |
P/CF | -1.02x |
P/FCF | -1.00x |
P/OCF | -1.02x |
PEG | -0.60x |
EV multiple | -2.76x |
About
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs).
Similar securities
Based on sector and market capitalization
Report issue











